Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is N/A as of Tuesday, October 6, 2026.
NET PROFIT MARGIN
N/A
Market Cap
$791.57M
Net Profit Margin
-14.52%
TTM Avg
7.87%
3Y Avg
-15.98%
5Y Avg
-254.57%
Market Cap
$792.28M
Net Profit Margin
-34.17%
TTM Avg
-136.69%
3Y Avg
-25443.25%
5Y Avg
-23332.75%
Market Cap
$777.94M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$772.90M
Net Profit Margin
-147.38%
TTM Avg
-372.93%
3Y Avg
-22199.44%
5Y Avg
-19748.48%
Market Cap
$796.08M
Net Profit Margin
-7.58%
TTM Avg
0.29%
3Y Avg
-4.57%
5Y Avg
-4.54%
Market Cap
$804.16M
Net Profit Margin
20.69%
TTM Avg
35.62%
3Y Avg
36.75%
5Y Avg
38.26%
Market Cap
$764.84M
Net Profit Margin
-4490.89%
TTM Avg
-2245.45%
3Y Avg
-2245.45%
5Y Avg
-2245.45%
Market Cap
$763.75M
Net Profit Margin
1.92%
TTM Avg
0.94%
3Y Avg
-28.83%
5Y Avg
-18.64%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $781.33M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $791.57M | -14.52% | 7.87% | -15.98% | -254.57% |
| Geron Corporation (GERN)vs › | $792.28M | -34.17% | -136.69% | -25443.25% | -23332.75% |
| Sana Biotechnology, Inc. (SANA)vs › | $777.94M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $772.90M | -147.38% | -372.93% | -22199.44% | -19748.48% |
| AdaptHealth Corp. (AHCO)vs › | $796.08M | -7.58% | 0.29% | -4.57% | -4.54% |
| InMode Ltd. (INMD)vs › | $804.16M | 20.69% | 35.62% | 36.75% | 38.26% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $764.84M | -4490.89% | -2245.45% | -2245.45% | -2245.45% |
| Mesa Laboratories, Inc. (MLAB)vs › | $763.75M | 1.92% | 0.94% | -28.83% | -18.64% |
| Ardelyx, Inc. (ARDX)vs › | $800.37M | -12.35% | -13.43% | -52.20% | -503.49% |
Operating Margin
N/A
Net Profit Margin
N/A
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
